Ipamorelin is the only growth hormone secretagogue described as fully selective for GH release. In its foundational study it triggered GH without raising cortisol or ACTH even at more than 200 times its GH ED50, the property that made it the preferred GHRP.
Ipamorelin is a growth hormone secretagogue, a peptide that prompts the pituitary to release a pulse of its own growth hormone. It does not contain or deliver growth hormone. It binds the ghrelin receptor on pituitary cells, triggers a brief GH pulse, and that GH drives hepatic IGF-1 production, the downstream signal behind most of what people associate with GH therapy. The benefits worth discussing are the ones that pulse can plausibly produce, and they split cleanly into what the pharmacology establishes and what has been measured in people.
- Ipamorelin is a selective growth hormone secretagogue that binds the ghrelin receptor, not the GHRH receptor [1]
- Its defining benefit is selectivity: it releases GH without raising cortisol or ACTH, unlike older GHRPs such as GHRP-6 and GHRP-2 [1]
- That selectivity data comes from swine and rats, not humans [1]
- No published human trial has tested ipamorelin for body composition, muscle, or anti-aging outcomes
- Its only published efficacy trial, for postoperative ileus, missed its primary endpoint [3]
- No FDA-approved ipamorelin product exists, and it appears on FDA’s safety-risk bulk substances list [4]
What Ipamorelin Is
Ipamorelin is a synthetic pentapeptide in the growth hormone secretagogue class, also called a GHRP (growth hormone-releasing peptide). It was introduced as the first selective growth hormone secretagogue [1]. Selective is the operative word. It separates ipamorelin from GHRP-6 and GHRP-2, which release GH but also raise cortisol and ACTH.
Mechanically it is a ghrelin receptor agonist. It binds GHS-R1a on pituitary somatotrophs, the same receptor the hunger hormone ghrelin uses. That is a different receptor from the one sermorelin and other GHRH analogs bind, which is why the two classes are combined in a stack rather than substituted for each other.
What Ipamorelin Does
Ipamorelin releases GH in a pulse, not a steady stream. The pituitary responds to the receptor signal by secreting stored GH, that GH reaches the liver, and the liver produces IGF-1. IGF-1 is the molecule that supports lean tissue, fat metabolism, and tissue repair. Because the release is pulsatile and the somatostatin feedback loop stays intact, the pattern resembles physiologic GH secretion more than a synthetic HGH injection does.
The selectivity is the mechanistic benefit that matters most. In the foundational study, ipamorelin did not release ACTH or cortisol at levels significantly different from GHRH stimulation even at doses more than 200 times its GH ED50, while GHRP-6 and GHRP-2 raised both [1]. Elevated cortisol works against the body composition goals people pursue GH therapy for, so a secretagogue that leaves it alone is the more rational choice within the class.
That comparison was run in swine and rats, not humans, so the cortisol claim rests on animal data [1]. The commonly repeated claim that ipamorelin uniquely spares prolactin is weaker than presented: in the same study none of the secretagogues tested affected prolactin, which makes it a property of the group in that experiment rather than an ipamorelin-specific edge.
The Benefits People Report
The reported benefits of ipamorelin are the benefits of a restored GH pulse, because that is the only thing it does. Read against the mechanism rather than the marketing, they sort by how well they are supported. None of the items below come from a trial of ipamorelin itself. They are inferred from what growth hormone and IGF-1 are known to do.
Consistent with GH physiology
- A measurable rise in IGF-1 when dosed correctly, which is the objective marker of response
- Gradual support of lean body mass when paired with training and adequate protein
- Reduction in visceral and abdominal fat over months rather than weeks
Reported by patients but not trial-confirmed for ipamorelin
- Improved sleep depth, often noted early, though controlled GHRH-analog sleep data is mixed
- Better post-exercise recovery
- Skin and connective tissue changes
The distinction is not academic. A benefit that follows from GH physiology is plausible. A benefit that has been measured in a controlled ipamorelin trial does not exist yet, and treating the first kind as if it were the second is where the marketing overreaches.
Where the Evidence Runs Out
No published or registered human trial has tested ipamorelin for body composition, muscle growth, fat loss, or anti-aging outcomes. Its clinical development targeted postoperative ileus, a gut motility problem, not physique. The only published efficacy trial found a median time to first tolerated meal of 25.3 hours versus 32.6 hours on placebo, which did not reach statistical significance [3], and development was discontinued afterward.
What is established is the class principle. In normal subjects, GH area under the curve was 686 for GHRH alone, 1787 for GHRP-6 alone, and 4111 for the combination, greater than the arithmetic sum [2]. That shows a GHRH analog plus a secretagogue is supra-additive in humans. It does not measure what ipamorelin does to fat or muscle in a treated adult, because no one has published that measurement.
Regulatory and Testing Status
There are no FDA-approved drug products containing ipamorelin in any form, so every prescription is compounded. FDA lists ipamorelin acetate among bulk drug substances for use in compounding that may present significant safety risks [4], citing immunogenicity potential, unnatural amino acids that complicate characterization, and serious adverse events including death reported when it was given intravenously for gastric motility.
For anyone subject to drug testing, ipamorelin is prohibited at all times under section S2.2.4 of the 2026 WADA Prohibited List [5], in the growth hormone secretagogues category alongside anamorelin and ibutamoren.
Every real ipamorelin benefit runs through the GH pulse, and the only way to confirm you are getting one is a baseline IGF-1 test and a 90-day retest. SystemLabs tests baseline IGF-1 before prescribing and builds protocols around GHRH analogs and selective secretagogues, so the response is measured rather than assumed.
Bottom Line
Frequently Asked Questions
What are the benefits of ipamorelin?
The one benefit specific to ipamorelin is selectivity: it releases growth hormone without raising cortisol or ACTH, which the older secretagogues GHRP-6 and GHRP-2 do not [1]. Its other reported benefits, such as IGF-1 elevation, lean mass support, and gradual visceral fat reduction, are the effects of a growth hormone pulse rather than findings from an ipamorelin trial. No human study has tested ipamorelin for those outcomes.
Does ipamorelin build muscle?
There is no published human trial of ipamorelin for muscle growth, so the honest answer is that its muscle benefit is inferred from growth hormone physiology, not measured. GH and IGF-1 support lean body mass, and ipamorelin raises both, but whether that becomes meaningful muscle depends on training, protein intake, and time. Marketing that presents muscle gain as proven for ipamorelin is overstating the evidence.
Is ipamorelin better than other GHRPs?
For most users, yes, because of selectivity. Ipamorelin releases growth hormone without the cortisol and ACTH increase seen with GHRP-6 and GHRP-2 [1], and elevated cortisol works against the body composition goals GH therapy is used for. The tradeoff is that its appetite effect and overall GH release are milder than GHRP-6, so it is the cleaner rather than the strongest secretagogue.
Does ipamorelin raise cortisol?
The selectivity data says it does not, but that data is from swine and rats rather than humans. In the foundational study, ipamorelin did not release cortisol or ACTH at levels significantly different from GHRH stimulation even at more than 200 times its GH ED50 [1]. No human cortisol study is available, so treat the claim as strongly suggested by animal data rather than demonstrated in people.
Is ipamorelin FDA approved?
No. FDA states there are no approved drug products containing ipamorelin in any form, and lists ipamorelin acetate among bulk substances for compounding that may present significant safety risks, citing immunogenicity potential, unnatural amino acids, and serious adverse events including death with intravenous use for gastric motility [4]. Every prescription is compounded and off-label.
How long does ipamorelin take to work?
IGF-1, the objective marker, is measurable within a few weeks of correct dosing, which is why a baseline test and a 90-day retest are the standard checkpoints. Any body composition change develops over months, not weeks, and tracks with training and diet. Because no ipamorelin trial measured these outcomes, timelines are extrapolated from growth hormone and GHRH-analog data rather than from ipamorelin itself.
References
- Ipamorelin, the first selective growth hormone secretagogue European Journal of Endocrinology, 1998. PMID: 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/
- Growth hormone (GH) secretion in active acromegaly after the combined administration of GH-releasing hormone and GH-releasing peptide-6 Journal of Clinical Endocrinology & Metabolism, 1994. PMID: 8045963. https://pubmed.ncbi.nlm.nih.gov/8045963/
- Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients International Journal of Colorectal Disease, 2014. PMID: 25331030. https://pubmed.ncbi.nlm.nih.gov/25331030/
- Certain bulk drug substances for use in compounding that may present significant safety risks FDA.gov, Human Drug Compounding, 2026. Content current as of 04/22/2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- The 2026 Prohibited List: International Standard, section S2.2.4 growth hormone releasing factors World Anti-Doping Agency, 2026. WADA 2026 Prohibited List. https://www.wada-ama.org/en/resources/2026-prohibited-list
